{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T05:29:10Z","timestamp":1792301350222,"version":"4.4.0"},"reference-count":133,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:00:00Z","timestamp":1719187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:00:00Z","timestamp":1719187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","award":["K23HL155898"],"award-info":[{"award-number":["K23HL155898"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006034","name":"University of Southern California","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006034","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Down syndrome is the most common genetic cause of intellectual disability and has previously been associated with a variety of autoimmune disorders affecting multiple organ systems. The high prevalence of autoimmune disease, in conjunction with other inflammatory and infectious diseases, in this population suggests an intrinsic immune dysregulation associated with triplication of chromosome 21. Emerging data on the role of chromosome 21 in interferon activation, cytokine production, and activation of B-cell mediated autoimmunity are emerging hypotheses that may explain the elevated prevalence of autoimmune thyroid disease, celiac disease, type I diabetes, autoimmune skin disease, and a variety of autoimmune neurologic conditions. As the life expectancy for individuals with Down syndrome increases, knowledge of the epidemiology, clinical features, management and underlying causes of these conditions will become increasingly important. Disorders such as Hashimoto\u2019s thyroiditis are prevalent in between 13 and 34% of individuals with Down syndrome but only 3% of the neurotypical population, a pattern similarly recognized in individuals with Celiac Disease (5.8% v 0.5\u20132%), alopecia areata (27.7% v. 2%), and vitiligo (4.4% v. 0.05\u20131.55%), respectively. Given the chronicity of autoimmune conditions, early identification and management can significantly impact the quality of life of individuals with Down syndrome. This comprehensive review will highlight common clinical autoimmune conditions observed in individuals with Down syndrome and explore our current understanding of the mechanisms of disease in this population.<\/jats:p>","DOI":"10.1007\/s12016-024-08996-2","type":"journal-article","created":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T04:02:13Z","timestamp":1719201733000},"page":"261-273","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Down Syndrome and Autoimmune Disease"],"prefix":"10.1007","volume":"66","author":[{"given":"Brian","family":"Hom","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie K.","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin N.","family":"Vogel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Nishimori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mellad M.","family":"Khoshnood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba","family":"Jafarpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepti","family":"Nagesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8350-8234","authenticated-orcid":false,"given":"Jonathan D.","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,24]]},"reference":[{"key":"8996_CR1","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/gim.2016.15","volume":"18","author":"G de Graaf","year":"2016","unstructured":"de Graaf G, Buckley F, Skotko BG (2016) Live births, natural losses, and elective terminations with Down syndrome in Massachusetts. Genet Med 18:459\u2013466","journal-title":"Genet Med"},{"key":"8996_CR2","first-page":"125","volume":"5","author":"M Kazemi","year":"2016","unstructured":"Kazemi M, Salehi M, Kheirollahi M (2016) Down syndrome: current status, challenges and future perspectives. Int J Mol Cell Med 5:125\u2013133","journal-title":"Int J Mol Cell Med"},{"key":"8996_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12929-015-0138-y","volume":"22","author":"A Asim","year":"2015","unstructured":"Asim A, Kumar A, Muthuswamy S, Jain S, Agarwal S (2015) Down syndrome: an insight of the disease. J Biomed Sci 22:41","journal-title":"J Biomed Sci"},{"key":"8996_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1097\/MED.0000000000000382","volume":"25","author":"R Whooten","year":"2018","unstructured":"Whooten R, Schmitt J, Schwartz A (2018) Endocrine manifestations of Down syndrome. Curr Opin Endocrinol Diabetes Obes 25:61\u201366","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"2","key":"8996_CR5","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3390\/genes12020268","volume":"12","author":"M Ferrari","year":"2021","unstructured":"Ferrari M, Stagi S (2021) Autoimmunity and genetic syndromes: a focus on down syndrome. Genes (Basel) 12(2):268","journal-title":"Genes (Basel)"},{"key":"8996_CR6","doi-asserted-by":"publisher","first-page":"543","DOI":"10.3389\/fendo.2020.00543","volume":"11","author":"EM Kyritsi","year":"2020","unstructured":"Kyritsi EM, Kanaka-Gantenbein C (2020) Autoimmune thyroid disease in specific genetic syndromes in childhood and adolescence. Front Endocrinol (Lausanne) 11:543","journal-title":"Front Endocrinol (Lausanne)"},{"key":"8996_CR7","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/icb.2012.9","volume":"90","author":"NA de Weerd","year":"2012","unstructured":"de Weerd NA, Nguyen T (2012) The interferons and their receptors\u2013distribution and regulation. Immunol Cell Biol 90:483\u2013491","journal-title":"Immunol Cell Biol"},{"key":"8996_CR8","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1007\/s10571-017-0514-0","volume":"38","author":"PN Alexandrov","year":"2018","unstructured":"Alexandrov PN, Percy ME, Lukiw WJ (2018) Chromosome 21-encoded microRNAs (mRNAs): impact on Down\u2019s syndrome and trisomy-21 linked disease. Cell Mol Neurobiol 38:769\u2013774","journal-title":"Cell Mol Neurobiol"},{"key":"8996_CR9","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/j.1365-2265.1994.tb02561.x","volume":"41","author":"LB Nicholson","year":"1994","unstructured":"Nicholson LB, Wong FS, Ewins DL et al (1994) Susceptibility to autoimmune thyroiditis in Down\u2019s syndrome is associated with the major histocompatibility class II DQA 0301 allele. Clin Endocrinol (Oxf) 41:381\u2013383","journal-title":"Clin Endocrinol (Oxf)"},{"key":"8996_CR10","doi-asserted-by":"publisher","first-page":"3185","DOI":"10.2337\/db06-0856","volume":"55","author":"KM Gillespie","year":"2006","unstructured":"Gillespie KM, Dix RJ, Williams AJ et al (2006) Islet autoimmunity in children with Down\u2019s syndrome. Diabetes 55:3185\u20133188","journal-title":"Diabetes"},{"key":"8996_CR11","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.2337\/db19-0045","volume":"68","author":"MB Johnson","year":"2019","unstructured":"Johnson MB, De Franco E, Greeley SAW et al (2019) Trisomy 21 is a cause of permanent neonatal diabetes that is autoimmune but not HLA associated. Diabetes 68:1528\u20131535","journal-title":"Diabetes"},{"key":"8996_CR12","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.2337\/dc12-1712","volume":"36","author":"RJ Aitken","year":"2013","unstructured":"Aitken RJ, Mehers KL, Williams AJ et al (2013) Early-onset, coexisting autoimmunity and decreased HLA-mediated susceptibility are the characteristics of diabetes in Down syndrome. Diabetes Care 36:1181\u20131185","journal-title":"Diabetes Care"},{"key":"8996_CR13","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/1096-8628(20010101)98:1<70::AID-AJMG1002>3.0.CO;2-G","volume":"98","author":"L Book","year":"2001","unstructured":"Book L, Hart A, Black J, Feolo M, Zone JJ, Neuhausen SL (2001) Prevalence and clinical characteristics of celiac disease in Downs syndrome in a US study. Am J Med Genet 98:70\u201374","journal-title":"Am J Med Genet"},{"key":"8996_CR14","first-page":"303","volume":"23","author":"P Failla","year":"1996","unstructured":"Failla P, Ruberto C, Pagano MC et al (1996) Celiac disease in Down\u2019s syndrome with HLA serological and molecular studies. J Pediatr Gastroenterol Nutr 23:303\u2013306","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"8996_CR15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11892-020-01318-8","volume":"20","author":"GL Mortimer","year":"2020","unstructured":"Mortimer GL, Gillespie KM (2020) Early onset of autoimmune diabetes in children with Down syndrome-two separate aetiologies or an immune system pre-programmed for autoimmunity? Curr Diab Rep 20:47","journal-title":"Curr Diab Rep"},{"key":"8996_CR16","doi-asserted-by":"publisher","first-page":"840","DOI":"10.3389\/fimmu.2020.00840","volume":"11","author":"Y Dieudonn\u00e9","year":"2020","unstructured":"Dieudonn\u00e9 Y, Uring-Lambert B, Jeljeli MM et al (2020) Immune defect in adults with Down syndrome: insights into a complex issue. Front Immunol 11:840","journal-title":"Front Immunol"},{"key":"8996_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100019","volume":"1","author":"JM Espinosa","year":"2020","unstructured":"Espinosa JM (2020) Down syndrome and COVID-19: a perfect storm? Cell Rep Med 1:100019","journal-title":"Cell Rep Med"},{"key":"8996_CR18","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/896758","volume":"2015","author":"S Stagi","year":"2015","unstructured":"Stagi S, Lapi E, Romano S et al (2015) Determinants of vitamin d levels in children and adolescents with down syndrome. Int J Endocrinol 2015:896758","journal-title":"Int J Endocrinol"},{"key":"8996_CR19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s11689-023-09503-y","volume":"15","author":"NK Boyd","year":"2023","unstructured":"Boyd NK, Nguyen J, Khoshnood MM et al (2023) Hypovitaminosis D in persons with Down syndrome and autism spectrum disorder. J Neurodev Disord 15:35","journal-title":"J Neurodev Disord"},{"key":"8996_CR20","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ridd.2016.06.018","volume":"57","author":"F Bertapelli","year":"2016","unstructured":"Bertapelli F, Pitetti K, Agiovlasitis S, Guerra-Junior G (2016) Overweight and obesity in children and adolescents with Down syndrome-prevalence, determinants, consequences, and interventions: a literature review. Res Dev Disabil 57:181\u2013192","journal-title":"Res Dev Disabil"},{"key":"8996_CR21","first-page":"36","volume":"90","author":"N AlAaraj","year":"2019","unstructured":"AlAaraj N, Soliman AT, Itani M, Khalil A, De Sanctis V (2019) Prevalence of thyroid dysfunctions in infants and children with Down syndrome (DS) and the effect of thyroxine treatment on linear growth and weight gain in treated subjects versus DS subjects with normal thyroid function: a controlled study. Acta Biomed 90:36\u201342","journal-title":"Acta Biomed"},{"key":"8996_CR22","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1136\/adc.79.3.242","volume":"79","author":"B Karlsson","year":"1998","unstructured":"Karlsson B, Gustafsson J, Hedov G, Ivarsson SA, Anner\u00e9n G (1998) Thyroid dysfunction in Down\u2019s syndrome: relation to age and thyroid autoimmunity. Arch Dis Child 79:242\u2013245","journal-title":"Arch Dis Child"},{"key":"8996_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2019.101367","volume":"33","author":"F Ragusa","year":"2019","unstructured":"Ragusa F, Fallahi P, Elia G et al (2019) Hashimotos\u2019 thyroiditis: epidemiology, pathogenesis, clinic and therapy. Best Pract Res Clin Endocrinol Metab 33:101367","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"8996_CR24","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1097\/MPG.0b013e31821a23d0","volume":"54","author":"S Husby","year":"2012","unstructured":"Husby S, Koletzko S, Korponay-Szab\u00f3 IR et al (2012) European Society for Pediatric Gastroenterology, Hepatology, and Nutrition guidelines for the diagnosis of coeliac disease. J Pediatr Gastroenterol Nutr 54:136\u2013160","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"8996_CR25","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/S0891-4222(99)00011-6","volume":"20","author":"FE Ali","year":"1999","unstructured":"Ali FE, Al-Busairi WA, Al-Mulla FA (1999) Treatment of hyperthyroidism in Down syndrome: case report and review of the literature. Res Dev Disabil 20:297\u2013303","journal-title":"Res Dev Disabil"},{"key":"8996_CR26","doi-asserted-by":"publisher","first-page":"S39","DOI":"10.1055\/a-1018-8963","volume":"127","author":"A Neu","year":"2019","unstructured":"Neu A, B\u00fcrger-B\u00fcsing J, Danne T et al (2019) Diagnosis, therapy and follow-up of diabetes mellitus in children and adolescents. Exp Clin Endocrinol Diabetes 127:S39-s72","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"1","key":"8996_CR27","first-page":"562","volume":"65","author":"DMF Pessoa","year":"2021","unstructured":"Pessoa DMF, Oliveira NLRSDP, Dantas GDS, Fernandes VDFT, Noronha RMD, Calliari LE (2021) Characteristics of type 1 diabetes mellitus in children and adolescents with Down\u2019s syndrome in an admixed population. Arch Endocrinol Metab 65(1):562\u2013569","journal-title":"Arch Endocrinol Metab"},{"key":"8996_CR28","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1093\/rheumatology\/41.10.1191","volume":"41","author":"B Padmakumar","year":"2002","unstructured":"Padmakumar B, Evans Jones LG, Sills JA (2002) Is arthritis more common in children with Down syndrome? Rheumatology (Oxford) 41:1191\u20131193","journal-title":"Rheumatology (Oxford)"},{"key":"8996_CR29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s40272-018-0322-0","volume":"21","author":"JT Jones","year":"2019","unstructured":"Jones JT, Talib N, Lovell D, Becker ML (2019) Clinical features and treatment of down syndrome arthropathy: experience from two US tertiary hospitals. Paediatr Drugs 21:33\u201339","journal-title":"Paediatr Drugs"},{"key":"8996_CR30","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1097\/MS9.0000000000001607","volume":"86","author":"M Kudsi","year":"2024","unstructured":"Kudsi M, Haj Ali D, Khalayli N, Jaber S, Almasri RNM (2024) Systemic lupus erythematosus and Down syndrome: a case report and literature review. Ann Med Surg (Lond) 86:1112\u20131115","journal-title":"Ann Med Surg (Lond)"},{"key":"8996_CR31","first-page":"253","volume":"21","author":"J Lima Estefan","year":"2013","unstructured":"Lima Estefan J, Queiroz M, Costa FF et al (2013) Clinical characteristics of alopecia areata in Down syndrome. Acta Dermatovenerol Croat 21:253\u2013258","journal-title":"Acta Dermatovenerol Croat"},{"key":"8996_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.724969","volume":"12","author":"JD Santoro","year":"2021","unstructured":"Santoro JD, Lee S, Wang AC et al (2021) Increased autoimmunity in individuals with down syndrome and moyamoya disease. Front Neurol 12:724969","journal-title":"Front Neurol"},{"key":"8996_CR33","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1161\/STROKEAHA.110.608471","volume":"42","author":"H Li","year":"2011","unstructured":"Li H, Zhang ZS, Dong ZN et al (2011) Increased thyroid function and elevated thyroid autoantibodies in pediatric patients with moyamoya disease: a case-control study. Stroke 42:1138\u20131139","journal-title":"Stroke"},{"key":"8996_CR34","unstructured":"Mincer DL, Jialal I (2024) Hashimoto Thyroiditis. [Updated 2023 Jul 29]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing.\u00a0 Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK459262\/"},{"key":"8996_CR35","doi-asserted-by":"publisher","first-page":"184","DOI":"10.26444\/aaem\/112331","volume":"27","author":"P Ihnatowicz","year":"2020","unstructured":"Ihnatowicz P, Drywie\u0144 M, W\u0105tor P, Wojsiat J (2020) The importance of nutritional factors and dietary management of Hashimoto\u2019s thyroiditis. Ann Agric Environ Med 27:184\u2013193","journal-title":"Ann Agric Environ Med"},{"key":"8996_CR36","first-page":"170","volume":"87","author":"MJ Pierce","year":"2017","unstructured":"Pierce MJ, LaFranchi SH, Pinter JD (2017) Characterization of thyroid abnormalities in a large cohort of children with Down syndrome Horm Res. Paediatr 87:170\u2013178","journal-title":"Paediatr"},{"key":"8996_CR37","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1530\/EJE-19-0823","volume":"182","author":"G Pepe","year":"2020","unstructured":"Pepe G, Corica D, De Sanctis L et al (2020) Prospective evaluation of autoimmune and non-autoimmune subclinical hypothyroidism in Down syndrome children. Eur J Endocrinol 182:385\u2013392","journal-title":"Eur J Endocrinol"},{"key":"8996_CR38","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1159\/000452912","volume":"48","author":"F Guaraldi","year":"2017","unstructured":"Guaraldi F, Rossetto Giaccherino R, Lanfranco F et al (2017) Endocrine autoimmunity in Down\u2019s syndrome. Front Horm Res 48:133\u2013146","journal-title":"Front Horm Res"},{"key":"8996_CR39","first-page":"132","volume":"89","author":"NH Amr","year":"2018","unstructured":"Amr NH (2018) Thyroid disorders in subjects with Down syndrome: an update. Acta Biomed 89:132\u2013139","journal-title":"Acta Biomed"},{"key":"8996_CR40","doi-asserted-by":"publisher","first-page":"521","DOI":"10.3389\/fimmu.2017.00521","volume":"8","author":"E Fr\u00f6hlich","year":"2017","unstructured":"Fr\u00f6hlich E, Wahl R (2017) Thyroid autoimmunity: role of anti-thyroid antibodies in thyroid and extra-thyroidal diseases. Front Immunol 8:521","journal-title":"Front Immunol"},{"key":"8996_CR41","volume-title":"Medicare Coverage of Routine Screening for Thyroid Dysfunction","author":"Institute of Medicine Committee on Medicare Coverage of Routine Thyroid S","year":"2003","unstructured":"Institute of Medicine Committee on Medicare Coverage of Routine Thyroid S (2003). In: Stone MB, Wallace RB (eds) Medicare Coverage of Routine Screening for Thyroid Dysfunction. National Academies Press (US)\u00a0Copyright 2003 by the National Academy of Sciences. All rights reserved, Washington (DC)"},{"key":"8996_CR42","unstructured":"Mathew P, Kaur J, Rawla P (2024) Hyperthyroidism. [Updated 2023 Mar 19]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing.\u00a0 Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK537053\/"},{"key":"8996_CR43","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/j.1365-2265.2008.03419.x","volume":"71","author":"A Goday-Arno","year":"2009","unstructured":"Goday-Arno A, Cerda-Esteva M, Flores-Le-Roux JA, Chillaron-Jordan JJ, Corretger JM, Cano-P\u00e9rez JF (2009) Hyperthyroidism in a population with Down syndrome (DS). Clin Endocrinol (Oxf) 71:110\u2013114","journal-title":"Clin Endocrinol (Oxf)"},{"key":"8996_CR44","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/j.ecl.2012.08.008","volume":"41","author":"E Graber","year":"2012","unstructured":"Graber E, Chacko E, Regelmann MO, Costin G, Rapaport R (2012) Down syndrome and thyroid function. Endocrinol Metab Clin North Am 41:735\u2013745","journal-title":"Endocrinol Metab Clin North Am"},{"key":"8996_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2020.101388","volume":"34","author":"A Antonelli","year":"2020","unstructured":"Antonelli A, Fallahi P, Elia G et al (2020) Graves\u2019 disease: clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy. Best Pract Res Clin Endocrinol Metab 34:101388","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"8996_CR46","doi-asserted-by":"publisher","first-page":"3813540","DOI":"10.1155\/2017\/3813540","volume":"2017","author":"J Liu","year":"2017","unstructured":"Liu J, Fu J, Xu Y, Wang G (2017) Antithyroid drug therapy for Graves\u2019 disease and implications for recurrence. Int J Endocrinol 2017:3813540","journal-title":"Int J Endocrinol"},{"key":"8996_CR47","doi-asserted-by":"publisher","first-page":"5387","DOI":"10.18632\/oncotarget.23624","volume":"9","author":"Y Du","year":"2018","unstructured":"Du Y, Shan LF, Cao ZZ, Feng JC, Cheng Y (2018) Prevalence of celiac disease in patients with Down syndrome: a meta-analysis. Oncotarget 9:5387\u20135396","journal-title":"Oncotarget"},{"key":"8996_CR48","doi-asserted-by":"publisher","first-page":"350","DOI":"10.3389\/fped.2018.00350","volume":"6","author":"JA Tye-Din","year":"2018","unstructured":"Tye-Din JA, Galipeau HJ, Agardh D (2018) Celiac disease: a review of current concepts in pathogenesis, prevention, and novel therapies. Front Pediatr 6:350","journal-title":"Front Pediatr"},{"key":"8996_CR49","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/cei.12454","volume":"179","author":"S Bj\u00f6rck","year":"2015","unstructured":"Bj\u00f6rck S, Lindehammer SR, Fex M, Agardh D (2015) Serum cytokine pattern in young children with screening detected coeliac disease. Clin Exp Immunol 179:230\u2013235","journal-title":"Clin Exp Immunol"},{"key":"8996_CR50","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4291\/wjgp.v8.i2.27","volume":"8","author":"I Parzanese","year":"2017","unstructured":"Parzanese I, Qehajaj D, Patrinicola F et al (2017) Celiac disease: from pathophysiology to treatment. World J Gastrointest Pathophysiol 8:27\u201338","journal-title":"World J Gastrointest Pathophysiol"},{"key":"8996_CR51","doi-asserted-by":"publisher","first-page":"264","DOI":"10.12998\/wjcc.v5.i7.264","volume":"5","author":"M Pavlovic","year":"2017","unstructured":"Pavlovic M, Berenji K, Bukurov M (2017) Screening of celiac disease in Down syndrome-old and new dilemmas. World J Clin Cases 5:264\u2013269","journal-title":"World J Clin Cases"},{"key":"8996_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2019.06.036","volume":"99","author":"CM Trovato","year":"2019","unstructured":"Trovato CM, Raucci U, Valitutti F et al (2019) Neuropsychiatric manifestations in celiac disease. Epilepsy Behav 99:106393","journal-title":"Epilepsy Behav"},{"key":"8996_CR53","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1136\/archdischild-2021-321770","volume":"107","author":"T O'Neill","year":"2022","unstructured":"O\u2019Neill T, Gillett PM, Wood P, Beattie D, Patil DJ, Chin RF (2022) Prevalence of neurological problems in a community-based sample of paediatric coeliac disease: a cross-sectional study. Arch Dis Child 107:377\u2013379","journal-title":"Arch Dis Child"},{"key":"8996_CR54","doi-asserted-by":"publisher","first-page":"3098","DOI":"10.1002\/ajmg.a.37879","volume":"170","author":"C Sharr","year":"2016","unstructured":"Sharr C, Lavigne J, Elsharkawi IM et al (2016) Detecting celiac disease in patients with Down syndrome. Am J Med Genet A 170:3098\u20133105","journal-title":"Am J Med Genet A"},{"key":"8996_CR55","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1007\/s00431-021-04318-283","volume":"181","author":"M Wessels","year":"2022","unstructured":"Wessels M, Dolinsek J, Castillejo G et al (2022) Follow-up practices for children and adolescents with celiac disease: results of an international survey. Eur J Pediatr 181:1213\u20131220. https:\/\/doi.org\/10.1007\/s00431-021-04318-283","journal-title":"Eur J Pediatr"},{"key":"8996_CR56","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1007\/s00125-006-0231-6","volume":"49","author":"R Bergholdt","year":"2006","unstructured":"Bergholdt R, Eising S, Nerup J, Pociot F (2006) Increased prevalence of Down\u2019s syndrome in individuals with type 1 diabetes in Denmark: a nationwide population-based study. Diabetologia 49:1179\u20131182","journal-title":"Diabetologia"},{"key":"8996_CR57","doi-asserted-by":"publisher","first-page":"359","DOI":"10.15585\/mmwr.mm6712a2","volume":"67","author":"KM Bullard","year":"2018","unstructured":"Bullard KM, Cowie CC, Lessem SE et al (2018) Prevalence of diagnosed diabetes in adults by diabetes type-United States, 2016. MMWR Morb Mortal Wkly Rep 67:359\u2013361","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"8996_CR58","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1007\/s00125-010-1686-z","volume":"53","author":"TR Rohrer","year":"2010","unstructured":"Rohrer TR, Hennes P, Thon A et al (2010) Down\u2019s syndrome in diabetic patients aged <20 years: an analysis of metabolic status, glycaemic control and autoimmunity in comparison with type 1 diabetes. Diabetologia 53:1070\u20131075","journal-title":"Diabetologia"},{"key":"8996_CR59","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/S0140-6736(69)91961-8","volume":"1","author":"PR Burch","year":"1969","unstructured":"Burch PR, Milunsky A (1969) Early-onset diabetes mellitus in the general and Down\u2019s syndrome populations. Genetics, aetiology, and pathogenesis. Lancet 1:554\u2013558","journal-title":"Lancet"},{"key":"8996_CR60","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.immuni.2010.04.001","volume":"32","author":"JA Todd","year":"2010","unstructured":"Todd JA (2010) Etiology of type 1 diabetes. Immunity 32:457\u2013467","journal-title":"Immunity"},{"key":"8996_CR61","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4239\/wjd.v11.i1.13","volume":"11","author":"AM Giwa","year":"2020","unstructured":"Giwa AM, Ahmed R, Omidian Z et al (2020) Current understandings of the pathogenesis of type 1 diabetes: genetics to environment. World J Diabetes 11:13\u201325","journal-title":"World J Diabetes"},{"key":"8996_CR62","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.2337\/dci18-0023","volume":"41","author":"JL Chiang","year":"2018","unstructured":"Chiang JL, Maahs DM, Garvey KC et al (2018) Type 1 diabetes in children and adolescents: a position statement by the American Diabetes Association. Diabetes Care 41:2026\u20132044","journal-title":"Diabetes Care"},{"key":"8996_CR63","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1002\/acr.24418","volume":"73","author":"JT Jones","year":"2021","unstructured":"Jones JT, Smith C, Becker ML, Lovell D (2021) Down syndrome-associated arthritis cohort in the new childhood arthritis and rheumatology research alliance registry: clinical characteristics, treatment, and outcomes. Arthritis Care Res (Hoboken) 73:1739\u20131745","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"8996_CR64","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2018-000890","volume":"5","author":"CM Foley","year":"2019","unstructured":"Foley CM, Deely DA, MacDermott EJ, Killeen OG (2019) Arthropathy of Down syndrome: an under-diagnosed inflammatory joint disease that warrants a name change. RMD Open 5:e000890","journal-title":"RMD Open"},{"key":"8996_CR65","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13023-017-0586-4","volume":"12","author":"L Aoust","year":"2017","unstructured":"Aoust L, Rossi-Semerano L, Kon\u00e9-Paut I, Dusser P (2017) Time to diagnosis in juvenile idiopathic arthritis: a french perspective. Orphanet J Rare Dis 12:43","journal-title":"Orphanet J Rare Dis"},{"key":"8996_CR66","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1053\/apmr.2001.21956","volume":"82","author":"RJ Palisano","year":"2001","unstructured":"Palisano RJ, Walter SD, Russell DJ et al (2001) Gross motor function of children with down syndrome: creation of motor growth curves. Arch Phys Med Rehabil 82:494\u2013500","journal-title":"Arch Phys Med Rehabil"},{"key":"8996_CR67","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1038\/s41586-023-05736-y","volume":"615","author":"L Malle","year":"2023","unstructured":"Malle L, Patel RS, Martin-Fernandez M et al (2023) Autoimmunity in Down\u2019s syndrome via cytokines, CD4 T cells and CD11c(+) B cells. Nature 615:305\u2013314","journal-title":"Nature"},{"key":"8996_CR68","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/s12969-021-00629-8","volume":"19","author":"LN Zaripova","year":"2021","unstructured":"Zaripova LN, Midgley A, Christmas SE, Beresford MW, Baildam EM, Oldershaw RA (2021) Juvenile idiopathic arthritis: from aetiopathogenesis to therapeutic approaches. Pediatr Rheumatol Online J 19:135","journal-title":"Pediatr Rheumatol Online J"},{"key":"8996_CR69","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/PHMT.S282646","volume":"13","author":"JT Jones","year":"2022","unstructured":"Jones JT, Kitchen J, Talib N (2022) Down syndrome-associated arthritis (DA): diagnostic and management challenges. Pediatric Health Med Ther 13:53\u201362","journal-title":"Pediatric Health Med Ther"},{"key":"8996_CR70","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1080\/14397595.2019.1709944","volume":"31","author":"Y Tanaka","year":"2021","unstructured":"Tanaka Y, Kuwana M, Fujii T et al (2021) 2019 Diagnostic criteria for mixed connective tissue disease (MCTD): from the Japan research committee of the ministry of health, labor, and welfare for systemic autoimmune diseases. Mod Rheumatol 31:29\u201333","journal-title":"Mod Rheumatol"},{"key":"8996_CR71","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0096868","volume":"9","author":"TJ Pikora","year":"2014","unstructured":"Pikora TJ, Bourke J, Bathgate K, Foley KR, Lennox N, Leonard H (2014) Health conditions and their impact among adolescents and young adults with Down syndrome. PLoS ONE 9:e96868","journal-title":"PLoS ONE"},{"key":"8996_CR72","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1111\/pde.14214","volume":"37","author":"JF Rork","year":"2020","unstructured":"Rork JF, McCormack L, Lal K, Wiss K, Belazarian L (2020) Dermatologic conditions in Down syndrome: a single-center retrospective chart review. Pediatr Dermatol 37:811\u2013816","journal-title":"Pediatr Dermatol"},{"key":"8996_CR73","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/jid.2013.464","volume":"134","author":"SA Mirzoyev","year":"2014","unstructured":"Mirzoyev SA, Schrum AG, Davis MDP, Torgerson RR (2014) Lifetime incidence risk of alopecia areata estimated at 2.1% by rochester epidemiology project, 1990\u20132009. J Invest Dermatol 134:1141\u20131142","journal-title":"J Invest Dermatol"},{"key":"8996_CR74","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1111\/bjd.15770","volume":"178","author":"A Garg","year":"2018","unstructured":"Garg A, Strunk A, Midura M, Papagermanos V, Pomerantz H (2018) Prevalence of hidradenitis suppurativa among patients with Down syndrome: a population-based cross-sectional analysis. Br J Dermatol 178:697\u2013703","journal-title":"Br J Dermatol"},{"key":"8996_CR75","doi-asserted-by":"publisher","first-page":"73","DOI":"10.3389\/fped.2020.00073","volume":"8","author":"D Huggard","year":"2020","unstructured":"Huggard D, Doherty DG, Molloy EJ (2020) Immune dysregulation in children with down syndrome. Front Pediatr 8:73","journal-title":"Front Pediatr"},{"key":"8996_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaad.2017.04.1141","volume":"78","author":"LC Strazzulla","year":"2018","unstructured":"Strazzulla LC, Wang EHC, Avila L et al (2018) Alopecia areata: disease characteristics, clinical evaluation, and new perspectives on pathogenesis. J Am Acad Dermatol 78:1\u201312","journal-title":"J Am Acad Dermatol"},{"key":"8996_CR77","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1111\/bjd.16808","volume":"179","author":"F Rajabi","year":"2018","unstructured":"Rajabi F, Drake LA, Senna MM, Rezaei N (2018) Alopecia areata: a review of disease pathogenesis. Br J Dermatol 179:1033\u20131048","journal-title":"Br J Dermatol"},{"issue":"Suppl 2","key":"8996_CR78","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/pde.14731","volume":"38","author":"C Ryan","year":"2021","unstructured":"Ryan C, Vellody K, Belazarian L, Rork JF (2021) Dermatologic conditions in Down syndrome. Pediatr Dermatol 38(Suppl 2):49\u201357","journal-title":"Pediatr Dermatol"},{"key":"8996_CR79","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1016\/j.celrep.2019.10.038","volume":"29","author":"KA Waugh","year":"2019","unstructured":"Waugh KA, Araya P, Pandey A et al (2019) Mass cytometry reveals global immune remodeling with multi-lineage hypersensitivity to type I interferon in down syndrome. Cell Rep 29:1893-1908.e1894","journal-title":"Cell Rep"},{"key":"8996_CR80","doi-asserted-by":"publisher","first-page":"e16220","DOI":"10.7554\/eLife.16220","volume":"5","author":"KD Sullivan","year":"2016","unstructured":"Sullivan KD, Lewis HC, Hill AA et al (2016) Trisomy 21 consistently activates the interferon response. Elife 5:e16220","journal-title":"Elife"},{"key":"8996_CR81","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s10238-020-00673-w","volume":"21","author":"A Sterkens","year":"2021","unstructured":"Sterkens A, Lambert J, Bervoets A (2021) Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options. Clin Exp Med 21:215\u2013230","journal-title":"Clin Exp Med"},{"key":"8996_CR82","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s12016-021-08883-0","volume":"61","author":"C Zhou","year":"2021","unstructured":"Zhou C, Li X, Wang C, Zhang J (2021) Alopecia areata: an update on etiopathogenesis, diagnosis, and management. Clin Rev Allergy Immunol 61:403\u2013423","journal-title":"Clin Rev Allergy Immunol"},{"key":"8996_CR83","doi-asserted-by":"publisher","first-page":"541","DOI":"10.12998\/wjcc.v2.i10.541","volume":"2","author":"JL Estefan","year":"2014","unstructured":"Estefan JL, Oliveira JC, Abad ED, Saintive SB, Porto LC, Ribeiro M (2014) HLA antigens in individuals with down syndrome and alopecia areata. World J Clin Cases 2:541\u2013545","journal-title":"World J Clin Cases"},{"key":"8996_CR84","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1111\/ajd.12941","volume":"60","author":"WC Cranwell","year":"2019","unstructured":"Cranwell WC, Lai VW, Photiou L et al (2019) Treatment of alopecia areata: an Australian expert consensus statement. Australas J Dermatol 60:163\u2013170","journal-title":"Australas J Dermatol"},{"key":"8996_CR85","unstructured":"Lepe K, Syed HA, Zito PM (2024) Alopecia Areata. [Updated 2024 Feb 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing.\u00a0 Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK537000\/"},{"key":"8996_CR86","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1001\/archneur.1969.00480090076012","volume":"20","author":"J Suzuki","year":"1969","unstructured":"Suzuki J, Takaku A (1969) Cerebrovascular \u201cmoyamoya\u201d disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol 20:288\u2013299","journal-title":"Arch Neurol"},{"key":"8996_CR87","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1161\/01.STR.14.1.104","volume":"14","author":"J Suzuki","year":"1983","unstructured":"Suzuki J, Kodama N (1983) Moyamoya disease\u2013a review. Stroke 14:104\u2013109","journal-title":"Stroke"},{"key":"8996_CR88","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1227\/NEU.0b013e31827b9beb","volume":"72","author":"DS Kainth","year":"2013","unstructured":"Kainth DS, Chaudhry SA, Kainth HS, Suri FK, Qureshi AI (2013) Prevalence and characteristics of concurrent down syndrome in patients with moyamoya disease. Neurosurgery 72:210\u2013215; discussion 215","journal-title":"Neurosurgery"},{"key":"8996_CR89","doi-asserted-by":"publisher","first-page":"e694","DOI":"10.1542\/peds.2005-0568","volume":"116","author":"A Jea","year":"2005","unstructured":"Jea A, Smith ER, Robertson R, Scott RM (2005) Moyamoya syndrome associated with Down syndrome: outcome after surgical revascularization. Pediatrics 116:e694-701","journal-title":"Pediatrics"},{"key":"8996_CR90","doi-asserted-by":"publisher","first-page":"201","DOI":"10.4103\/JPN.JPN_116_17","volume":"13","author":"P Kumar","year":"2018","unstructured":"Kumar P, Panigrahi I, Sankhyan N, Ahuja C, Goyadi PK (2018) Down syndrome with moyamoya disease: a case series. J Pediatr Neurosci 13:201\u2013204","journal-title":"J Pediatr Neurosci"},{"key":"8996_CR91","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2176\/jns-nmc.2022-0072","volume":"62","author":"S Kuroda","year":"2022","unstructured":"Kuroda S, Fujimura M, Takahashi J et al (2022) Diagnostic criteria for moyamoya disease-2021 revised version. Neurol Med Chir (Tokyo) 62:307\u2013312","journal-title":"Neurol Med Chir (Tokyo)"},{"issue":"4","key":"8996_CR92","doi-asserted-by":"publisher","first-page":"e20180840","DOI":"10.1542\/peds.2018-0840","volume":"142","author":"JD Santoro","year":"2018","unstructured":"Santoro JD, Lee S, Mlynash M et al (2018) Blood Pressure Elevation and Risk of Moyamoya Syndrome in Patients With Trisomy 21. Pediatrics. 142(4):e20180840. https:\/\/doi.org\/10.1542\/peds.2018-0840","journal-title":"Pediatrics."},{"key":"8996_CR93","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s11689-022-09446-w","volume":"14","author":"JD Santoro","year":"2022","unstructured":"Santoro JD, Partridge R, Tanna R et al (2022) Evidence of neuroinflammation and immunotherapy responsiveness in individuals with down syndrome regression disorder. J Neurodev Disord 14:35","journal-title":"J Neurodev Disord"},{"key":"8996_CR94","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.940175","volume":"13","author":"JD Santoro","year":"2022","unstructured":"Santoro JD, Patel L, Kammeyer R et al (2022) Assessment and diagnosis of Down syndrome regression disorder: international expert consensus. Front Neurol 13:940175","journal-title":"Front Neurol"},{"issue":"10","key":"8996_CR95","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1002\/ajmg.a.62922","volume":"188","author":"SL Santoro","year":"2022","unstructured":"Santoro SL, Baumer NT, Cornacchia M et al (2022) Unexplained regression in Down syndrome: management of 51 patients in an international patient database. Am J Med Genet A 188(10):3049\u201362","journal-title":"Am J Med Genet A"},{"key":"8996_CR96","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/s41436-019-0706-8","volume":"22","author":"SL Santoro","year":"2020","unstructured":"Santoro SL, Cannon S, Capone G et al (2020) Unexplained regression in Down syndrome: 35 cases from an international Down syndrome database. Genet Med 22:767\u2013776","journal-title":"Genet Med"},{"key":"8996_CR97","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1177\/0883073814554654","volume":"30","author":"G Worley","year":"2015","unstructured":"Worley G, Crissman BG, Cadogan E, Milleson C, Adkins DW, Kishnani PS (2015) Down syndrome disintegrative disorder: new-onset autistic regression, dementia, and insomnia in older children and adolescents with down syndrome. J Child Neurol 30:1147\u20131152","journal-title":"J Child Neurol"},{"issue":"6","key":"8996_CR98","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/brainsci7060057","volume":"7","author":"C Mircher","year":"2017","unstructured":"Mircher C, Cieuta-Walti C, Marey I et al (2017) Acute regression in young people with Down syndrome. Brain Sci 7(6):57","journal-title":"Brain Sci"},{"issue":"9","key":"8996_CR99","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.3390\/brainsci11091197","volume":"11","author":"M Walpert","year":"2021","unstructured":"Walpert M, Zaman S, Holland A (2021) A systematic review of unexplained early regression in adolescents and adults with Down syndrome. Brain Sci 11(9):1197","journal-title":"Brain Sci"},{"key":"8996_CR100","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41398-023-02579-z","volume":"13","author":"JD Santoro","year":"2023","unstructured":"Santoro JD, Spinazzi NA, Filipink RA et al (2023) Immunotherapy responsiveness and risk of relapse in Down syndrome regression disorder. Transl Psychiatry 13:276","journal-title":"Transl Psychiatry"},{"issue":"4","key":"8996_CR101","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/acn3.52023","volume":"11","author":"JD Santoro","year":"2024","unstructured":"Santoro JD, Khoshnood MM, Jafarpour S et al (2024) Neuroimaging abnormalities associated with immunotherapy responsiveness in Down syndrome regression disorder. Ann Clin Transl Neurol 11(4):1034\u20131045. https:\/\/doi.org\/10.1002\/acn3.52023","journal-title":"Ann Clin Transl Neurol"},{"key":"8996_CR102","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s10875-020-00803-9","volume":"40","author":"XF Kong","year":"2020","unstructured":"Kong XF, Worley L, Rinchai D et al (2020) Three copies of four interferon receptor genes underlie a mild type I interferonopathy in Down syndrome. J Clin Immunol 40:807\u2013819","journal-title":"J Clin Immunol"},{"key":"8996_CR103","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1086\/519248","volume":"81","author":"P Prandini","year":"2007","unstructured":"Prandini P, Deutsch S, Lyle R et al (2007) Natural gene-expression variation in Down syndrome modulates the outcome of gene-dosage imbalance. Am J Hum Genet 81:252\u2013263","journal-title":"Am J Hum Genet"},{"key":"8996_CR104","doi-asserted-by":"publisher","DOI":"10.1111\/sji.13314","volume":"98","author":"A Liu","year":"2023","unstructured":"Liu A, Ying S (2023) Aicardi-Gouti\u00e8res syndrome: a monogenic type I interferonopathy. Scand J Immunol 98:e13314","journal-title":"Scand J Immunol"},{"key":"8996_CR105","first-page":"1231","volume":"18","author":"CW Cheng","year":"2022","unstructured":"Cheng CW, Tang KT, Fang WF, Lee TI, Lin JD (2022) Differential serum interferon-\u03b2 levels in autoimmune thyroid diseases. Arch Med Sci 18:1231\u20131240","journal-title":"Arch Med Sci"},{"key":"8996_CR106","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1080\/08916934.2020.1755965","volume":"53","author":"CW Cheng","year":"2020","unstructured":"Cheng CW, Wu CZ, Tang KT, Fang WF, Lin JD (2020) Simultaneous measurement of twenty-nine circulating cytokines and growth factors in female patients with overt autoimmune thyroid diseases. Autoimmunity 53:261\u2013269","journal-title":"Autoimmunity"},{"key":"8996_CR107","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.2337\/db16-0616","volume":"65","author":"M Lundberg","year":"2016","unstructured":"Lundberg M, Krogvold L, Kuric E, Dahl-J\u00f8rgensen K, Skog O (2016) Expression of interferon-stimulated genes in insulitic pancreatic islets of patients recently diagnosed with type 1 diabetes. Diabetes 65:3104\u20133110","journal-title":"Diabetes"},{"key":"8996_CR108","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S0140-6736(87)91128-7","volume":"2","author":"AK Foulis","year":"1987","unstructured":"Foulis AK, Farquharson MA, Meager A (1987) Immunoreactive alpha-interferon in insulin-secreting beta cells in type 1 diabetes mellitus. Lancet 2:1423\u20131427","journal-title":"Lancet"},{"key":"8996_CR109","doi-asserted-by":"publisher","first-page":"2450401","DOI":"10.1155\/2017\/2450401","volume":"2017","author":"D Jim\u00e9nez-Gallo","year":"2017","unstructured":"Jim\u00e9nez-Gallo D, de la Varga-Mart\u00ednez R, Ossorio-Garc\u00eda L, Albarr\u00e1n-Planelles C, Rodr\u00edguez C, Linares-Barrios M (2017) The clinical significance of increased serum proinflammatory cytokines, C-reactive protein, and erythrocyte sedimentation rate in patients with Hidradenitis suppurativa. Mediators Inflamm 2017:2450401","journal-title":"Mediators Inflamm"},{"key":"8996_CR110","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13718","volume":"33","author":"N Agamia","year":"2020","unstructured":"Agamia N, Apalla Z, El Achy S, Abdelmaksoud E, Kandil N, Abozeid S (2020) Interferon-gamma serum level and immunohistochemical expression of CD8 cells in tissue biopsies in patients with alopecia areata in correlation with trichoscopic findings. Dermatol Ther 33:e13718","journal-title":"Dermatol Ther"},{"issue":"4","key":"8996_CR111","doi-asserted-by":"publisher","first-page":"e2250281","DOI":"10.1002\/eji.202250281","volume":"54","author":"H Liu","year":"2024","unstructured":"Liu H, Wang Y, Le Q, Tong J, Wang H (2024) The IFN-\u03b3-CXCL9\/CXCL10-CXCR3 axis in vitiligo: Pathological mechanism and treatment. Eur J Immunol 54(4):e2250281. https:\/\/doi.org\/10.1002\/eji.202250281","journal-title":"Eur J Immunol"},{"issue":"14","key":"8996_CR112","doi-asserted-by":"publisher","first-page":"5187","DOI":"10.2147\/JIR.S280953","volume":"7","author":"H Chung","year":"2021","unstructured":"Chung H, Green PHR, Wang TC, Kong XF (2021) Interferon-Driven Immune Dysregulation in Down Syndrome: A Review of the Evidence. J Inflamm Res 7(14):5187\u20135200. https:\/\/doi.org\/10.2147\/JIR.S280953. PMID: 34675597; PMCID: PMC8504936","journal-title":"J Inflamm Res"},{"key":"8996_CR113","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1038\/nri1226","volume":"3","author":"K Shuai","year":"2003","unstructured":"Shuai K, Liu B (2003) Regulation of JAK-STAT signalling in the immune system. Nat Rev Immunol 3:900\u2013911","journal-title":"Nat Rev Immunol"},{"key":"8996_CR114","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.2741\/4008","volume":"17","author":"J Strebovsky","year":"2012","unstructured":"Strebovsky J, Walker P, Dalpke AH (2012) Suppressor of cytokine signaling proteins as regulators of innate immune signaling. Front Biosci (Landmark Ed) 17:1627\u20131639","journal-title":"Front Biosci (Landmark Ed)"},{"key":"8996_CR115","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fimmu.2012.00020","volume":"3","author":"A Yoshimura","year":"2012","unstructured":"Yoshimura A, Suzuki M, Sakaguchi R, Hanada T, Yasukawa H (2012) SOCS, inflammation, and autoimmunity. Front Immunol 3:20","journal-title":"Front Immunol"},{"key":"8996_CR116","doi-asserted-by":"publisher","first-page":"3029","DOI":"10.1007\/s00018-009-0061-z","volume":"66","author":"MM Rytinki","year":"2009","unstructured":"Rytinki MM, Kaikkonen S, Pehkonen P, J\u00e4\u00e4skel\u00e4inen T, Palvimo JJ (2009) PIAS proteins: pleiotropic interactors associated with SUMO. Cell Mol Life Sci 66:3029\u20133041","journal-title":"Cell Mol Life Sci"},{"key":"8996_CR117","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1089\/jir.2011.0065","volume":"31","author":"KD Moudgil","year":"2011","unstructured":"Moudgil KD, Choubey D (2011) Cytokines in autoimmunity: role in induction, regulation, and treatment. J Interferon Cytokine Res 31:695\u2013703","journal-title":"J Interferon Cytokine Res"},{"key":"8996_CR118","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1093\/intimm\/dxv063","volume":"28","author":"Y Lai","year":"2016","unstructured":"Lai Y, Dong C (2016) Therapeutic antibodies that target inflammatory cytokines in autoimmune diseases. Int Immunol 28:181\u2013188","journal-title":"Int Immunol"},{"key":"8996_CR119","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2300733120","volume":"120","author":"AS Thomann","year":"2023","unstructured":"Thomann AS, McQuade CA, Pinju\u0161i\u0107 K et al (2023) A B cell-driven EAE mouse model reveals the impact of B cell-derived cytokines on CNS autoimmunity. Proc Natl Acad Sci U S A 120:e2300733120","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8996_CR120","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1093\/cei\/uxad103","volume":"215","author":"AN Ozdag Acarli","year":"2024","unstructured":"Ozdag Acarli AN, Tuzun E, Sanli E et al (2024) Disease activity in chronic inflammatory demyelinating polyneuropathy: association between circulating B-cell subsets, cytokine levels, and clinical outcomes. Clin Exp Immunol 215:65\u201378","journal-title":"Clin Exp Immunol"},{"key":"8996_CR121","doi-asserted-by":"publisher","first-page":"13231","DOI":"10.1038\/s41598-023-40239-w","volume":"13","author":"M Zhao","year":"2023","unstructured":"Zhao M, Chen L, Yang J et al (2023) Interleukin 6 exacerbates the progression of warm autoimmune hemolytic anemia by influencing the activity and function of B cells. Sci Rep 13:13231","journal-title":"Sci Rep"},{"key":"8996_CR122","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1136\/ard-2022-222605","volume":"81","author":"Y Qin","year":"2022","unstructured":"Qin Y, Cai ML, Jin HZ et al (2022) Age-associated B cells contribute to the pathogenesis of rheumatoid arthritis by inducing activation of fibroblast-like synoviocytes via TNF-\u03b1-mediated ERK1\/2 and JAK-STAT1 pathways. Ann Rheum Dis 81:1504\u20131514","journal-title":"Ann Rheum Dis"},{"key":"8996_CR123","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.jns.2013.03.002","volume":"333","author":"A Rostami","year":"2013","unstructured":"Rostami A, Ciric B (2013) Role of Th17 cells in the pathogenesis of CNS inflammatory demyelination. J Neurol Sci 333:76\u201387","journal-title":"J Neurol Sci"},{"key":"8996_CR124","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202101734RRR","volume":"36","author":"J Chen","year":"2022","unstructured":"Chen J, Li X, Zeng P et al (2022) Lamina propria interleukin 17 A aggravates natural killer T-cell activation in autoimmune hepatitis. Faseb j 36:e22346","journal-title":"Faseb j"},{"key":"8996_CR125","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-immunol-061020-053702","volume":"39","author":"C Dong","year":"2021","unstructured":"Dong C (2021) Cytokine regulation and function in T cells. Annu Rev Immunol 39:51\u201376","journal-title":"Annu Rev Immunol"},{"key":"8996_CR126","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.jcmgh.2021.08.019","volume":"13","author":"F Wang","year":"2022","unstructured":"Wang F, Zhang X, Liu W et al (2022) Activated natural killer cell promotes nonalcoholic steatohepatitis through mediating JAK\/STAT pathway. Cell Mol Gastroenterol Hepatol 13:257\u2013274","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"8996_CR127","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.3389\/fimmu.2019.02590","volume":"10","author":"D Gotthardt","year":"2019","unstructured":"Gotthardt D, Trifinopoulos J, Sexl V, Putz EM (2019) JAK\/STAT cytokine signaling at the crossroad of NK cell development and maturation. Front Immunol 10:2590","journal-title":"Front Immunol"},{"issue":"3","key":"8996_CR128","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s40261-024-01348-0","volume":"44","author":"L Westerkam","year":"2024","unstructured":"Westerkam L, Pearson L, Sayed C (2024) Safety and Efficacy of Biologic Medications and Janus Kinase Inhibitors in Patients with Down Syndrome: A Retrospective Cohort Study. Clin Drug Investig 44(3):219\u2013222. https:\/\/doi.org\/10.1007\/s40261-024-01348-0","journal-title":"Clin Drug Investig"},{"key":"8996_CR129","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1007\/s12016-011-8294-7","volume":"42","author":"MF Cusick","year":"2012","unstructured":"Cusick MF, Libbey JE, Fujinami RS (2012) Molecular mimicry as a mechanism of autoimmune disease. Clin Rev Allergy Immunol 42:102\u2013111","journal-title":"Clin Rev Allergy Immunol"},{"key":"8996_CR130","doi-asserted-by":"publisher","first-page":"7864","DOI":"10.1073\/pnas.1522730113","volume":"113","author":"SM Br\u00e4ndle","year":"2016","unstructured":"Br\u00e4ndle SM, Obermeier B, Senel M et al (2016) Distinct oligoclonal band antibodies in multiple sclerosis recognize ubiquitous self-proteins. Proc Natl Acad Sci U S A 113:7864\u20137869","journal-title":"Proc Natl Acad Sci U S A"},{"key":"8996_CR131","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s00125-019-05032-3","volume":"63","author":"LA Claessens","year":"2020","unstructured":"Claessens LA, Wesselius J, van Lummel M et al (2020) Clinical and genetic correlates of islet-autoimmune signatures in juvenile-onset type 1 diabetes. Diabetologia 63:351\u2013361","journal-title":"Diabetologia"},{"key":"8996_CR132","doi-asserted-by":"publisher","first-page":"86","DOI":"10.17294\/2330-0698.1824","volume":"8","author":"B Chicoine","year":"2021","unstructured":"Chicoine B, Rivelli A, Fitzpatrick V, Chicoine L, Jia G, Rzhetsky A (2021) Prevalence of common disease conditions in a large cohort of individuals with down syndrome in the United States. J Patient Cent Res Rev 8:86\u201397","journal-title":"J Patient Cent Res Rev"},{"key":"8996_CR133","doi-asserted-by":"publisher","first-page":"eabi4888","DOI":"10.1126\/scitranslmed.abi4888","volume":"14","author":"K Lambert","year":"2022","unstructured":"Lambert K, Moo KG, Arnett A et al (2022) Deep immune phenotyping reveals similarities between aging, Down syndrome, and autoimmunity. Sci Transl Med 14:eabi4888","journal-title":"Sci Transl Med"}],"container-title":["Clinical Reviews in Allergy &amp; Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-024-08996-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-024-08996-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-024-08996-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T10:02:16Z","timestamp":1727172136000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-024-08996-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,24]]},"references-count":133,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,6]]}},"alternative-id":["8996"],"URL":"https:\/\/doi.org\/10.1007\/s12016-024-08996-2","relation":{},"ISSN":["1559-0267"],"issn-type":[{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,24]]},"assertion":[{"value":"8 June 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}